Recent news that the US Food and Drug Administration (FDA) will ask cell and gene therapy (CGT) developers to provide more consistent evidence with their submissions has resulted in drug makers delaying development plans — and working on new ways to address the agency’s concerns
25th October 2022: Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline. Using Paradigm4’s cloud-based scientific analytics platform and data from the UK Biobank, Alnylam has identified
Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline.
Popular opinion is that two big shifts have changed the game for bioinformatics. The first is a technology development—single cell ‘omics—that began just over 10 years ago, the other is a more recent move to a new model of drug discovery that looks to leverage the vast amounts of human
